Euda Health Holdings Limited Dossier
|
SectorHealth Care IndustryHealth Care Providers & Services Beta (adjusted)0.78 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $15.91Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $47.6M Shares Outstanding 3M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary EUDA Health Holdings Ltd is transitioning its business model toward proactive, longevity-focused healthcare and wellness products in Southeast Asia and China. While the company has successfully regained compliance with Nasdaq's minimum market value requirements and demonstrated a 70% year-over-year revenue increase in FY 2025, it continues to face severe financial constraints. These include a significant working capital deficiency, ongoing net losses, and a negative shareholder equity position, which have led to persistent going concern warnings from its auditors. Given these high operational risks balanced against its strategic pivot into high-growth longevity sectors, a Hold recommendation is advised. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$55.00 Mean target$55.00 High · most bullish analyst$55.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company fails to secure sufficient financing to cover its working capital deficit, or loses key distribution rights for its stem cell therapy packages. This leads to further liquidity distress, potential breach of Nasdaq listing rules, and severe equity dilution or restructuring. Base CaseCentral scenario The company continues to stabilize its core property management and holistic wellness segments while gradually expanding its longevity product lines (such as the Helixé and Regenixé brands). It manages to secure periodic private placements to meet short-term obligations, avoiding delisting but experiencing limited valuation upside due to ongoing dilution and structural profitability challenges. Bull CaseUpside scenario Successful commercialization of its regenerative medicine pipeline (such as the Helixé 2.0 and Regenixé product lines) and the integration of the QB utility token platform to drive high-margin consumer wellness revenue and digital engagement across Southeast Asia. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |